Aleglitazar

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Template:Chembox new

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Aleglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by Hoffmann–La Roche for the treatment of type II diabetes. It is currently in phase II clinical trials.[1]

References

  1. ↑ ClinicalTrials.gov. "A Study of Aleglitazar in Patients With Type 2 Diabetes". United States National Institutes of Health. Retrieved 2008-03-19.

Template:Pharma-stub Template:Oral hypoglycemics

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Aleglitazar&oldid=668034"